secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001104659-26-028595
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec settles PEDMARK patent litigation; Cipla barred from generic until 2033
------------------------------------------------------------------------------

- Lawsuit dismissed; each party bears its own costs.
- Cipla agrees not to launch generic sodium thiosulfate in U.S. until September 1, 2033, subject to earlier entry under specified circumstances.
- Settlement covers Cipla's ANDA for generic PEDMARK, resolving litigation in D.N.J.
- Press release issued March 16, 2026 announcing the agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926028595/0001104659-26-028595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926028595/fencf-20260316x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-028595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer